Evidence map›Paper›PMID 41931242›Full record

ArticleDrugs in R&D2026

Updated Viloxazine Pharmacology: Experiments Establish Norepinephrine Transporter Occupancy and Serotonin 5-HT

Jennie Garcia-Olivares, Brittney Yegla, Jennifer Koch, Chungping Yu, Jonathan Rubin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drugs in R&D, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jennie Garcia-OlivaresSupernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA. jgarciaolivares@supernus.com.ORCID http://orcid.org/0000-0002-6164-0744
Brittney YeglaSupernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA.
Jennifer KochSupernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA.
Chungping YuSupernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA.
Jonathan RubinSupernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesViloxazine, which has been used to treat depression and attention-deficit/hyperactivity disorder (ADHD), has been termed a moderate-affinity, selective norepinephrine reuptake inhibitor based on high selectivity for norepinephrine relative to serotonin and dopamine transporters. However, accumulated research suggests a more complex mechanism of action, based on studies showing activity at serotonin 5-HT

methodsUsing in vitro binding competition and functional assays and ex vivo receptor occupancy studies in rats, we assessed viloxazine activity at human NET isoforms and 5-HT

resultsViloxazine showed moderate binding affinity for NET (inhibition constant [K

conclusionsThese results validate previous experiments showing that viloxazine, in addition to displaying high NET occupancy, acts as a partial agonist at 5-HT

Indexed as

Norepinephrine Plasma Membrane Transport ProteinsReceptor, Serotonin, 5-HT2BReceptor, Serotonin, 5-HT2CReceptors, SerotoninAnimalsHumansMaleProtein BindingRatsRats, Sprague-DawleyNorepinephrine Plasma Membrane Transport ProteinsReceptor, Serotonin, 5-HT2BReceptor, Serotonin, 5-HT2CReceptors, Serotoninserotonin 7 receptor

Identifiers

PMID41931242
PMCPMC13076852

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.